We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
News

Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers

Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
News

Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vermillion, Inc., a molecular diagnostics company, has announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of breast cancer and to the measurement of the biomarkers by mass spectrometry.

"The notice of allowance for this breast cancer biomarker patent is additional validation of our approach to intellectual property protection. We view the increasing breadth of our patent portfolio as a significant corporate asset," said Gail S. Page, CEO and Chairperson of the Board of Directors of Vermillion.

Advertisement